Christopher Wells

发表

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

S. Knapp, O. Fedorov, C. Bountra, 2013, Proceedings of the National Academy of Sciences.

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

L. Wodicka, S. Knapp, O. Fedorov, 2014, Nature chemical biology.

Dynamic phase separation of the androgen receptor and its coactivators to regulate gene expression

Jennifer M. Bui, M. Gleave, Yuzhuo Wang, 2021, bioRxiv.

Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance

S. Knapp, P. Biggin, O. Fedorov, 2015, Science Advances.

[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains

S. Knapp, O. Fedorov, S. Müller, 2013, Journal of medicinal chemistry.

Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands

S. Knapp, O. Fedorov, P. Brennan, 2013, Journal of medicinal chemistry.

Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

S. Knapp, O. Fedorov, M. Bunnage, 2014, Journal of the American Chemical Society.

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

S. Knapp, O. Fedorov, P. Wordsworth, 2015, Proceedings of the National Academy of Sciences.

Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching

A. Gingras, S. Knapp, S. Müller, 2014, Epigenetics & Chromatin.

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Andrew J. Bannister, S. Robson, S. Knapp, 2015, Cancer research.

Maintenance of muscle myosin levels in adult C. elegans requires both the double bromodomain protein BET-1 and sumoylation

L. B. Snoek, S. Knapp, G. Poulin, 2013, Biology Open.

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia

A. Gingras, S. Knapp, O. Dovey, 2016, Science Advances.